Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385671 · ClinicalTrials.gov registry record · Phase 4
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 407
- Enrollment target
NCT00385671 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 407 participants.
The verdict
NCT00385671, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 407 participants
- Enrollment target
Study Summary
To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin.
Interventions
- DRUG gabapentin
- DRUG pregabalin
- DRUG duloxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385671
The ClinicalTrials.gov registry entry for NCT00385671 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which gabapentin is the first listed.
NCT00385671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385671 about?
NCT00385671 is a clinical study titled "An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain". To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin.
What is the current status of trial NCT00385671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 407 participants. The study started on 2006-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00385671?
The interventions under investigation include: gabapentin (DRUG), pregabalin (DRUG), duloxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00385671?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.